Xylazine is a non-opioid sedative not approved for human use that is increasingly found as an adulterant in the illicit drug supply. Researchers, public health officials, and community leaders are working to address xylazine in prevention, clinical care, and overdose prevention.
Panelists will discuss the prevalence and toxicology of xylazine, overdose response strategies, and what healthcare professionals and criminal justice practitioners can do to respond. This webinar is sponsored by the Justice Community Opioid Innovation Network (JCOIN), an initiative funded by the National Institute on Drug Abuse (NIDA). The webinar is also in partnership with the Association of State and Territorial Health Officials (ASTHO), and the Addiction Policy Forum.
- Richa Ranade, MPH, Senior Director of Overdose Prevention, Association of State and Territorial Health Officials
- Mbabazi Kariisa, Ph.D., Health Scientist, Division of Overdose Prevention in National Center for Injury Prevention and Control, Centers for Disease Control and Prevention (CDC)
- Traci Green, Ph.D., Professor and Director of the Opioid Policy Research Collaborative, Brandeis University
- Megan Reed, Ph.D., MPH, Research Assistant Professor, Thomas Jefferson University
- Julia Zur, Ph.D., Program Officer, Services Research Branch, National Institute on Drug Abuse (NIDA)
Led by the National Institute on Drug Abuse (NIDA) and funded by the NIH HEAL Initiative℠, JCOIN is a groundbreaking initiative designed to advance scientific knowledge on effective policies, practices, and interventions to address the opioid crisis among justice-involved individuals, by partnering researchers with justice agencies and community health programs.